Floatz logo

FILGRASTIM

Amyloidosis

Memorial Sloan Kettering Cancer Centerprotein_peptidePhase 2Active
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
51/ 100
Competitive Position
89/ 100

Competitive context

13 Active assets in the Amyloidosis cohort.

Asset / SponsorPhaseRating
DEXAMETHASONE
Ascentage Pharma Group Inc.
Phase 3BB
Cyclophosphamide
University of Alabama at Birmingham
Phase 2BB
cc-5013
Ascentage Pharma Group Inc.
Phase 3BB
Acoramidis
Eidos Therapeutics, a BridgeBio company
Phase 3BB
Tegsedi
Brigham and Women's Hospital
Phase 3BB

View all 29 →

Same molecule, other indications

FILGRASTIM is also rated in:

plasma cell myelomaDormant
BBB
Indicative ·
79 / 100
View asset →
Burkitt lymphomaDormant
BBB
Indicative ·
78 / 100
View asset →
Hodgkins lymphomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →